Natera Inc Form 4 Filings

Natera, Inc. (NTRA) reported that Chief Executive Officer and President Steven Leonard Chapman sold 1,698 shares of common stock on September 1, 2026 in an open-market or private transaction at a price of $320.99 per share. After this sale, he directly holds 98,199 shares of Natera common stock. The sale was effected under a Rule 10b5-1 trading plan adopted on December 11, 2023 and amended on December 2, 2024 and March 5, 2026.

Natera, Inc. (NTRA) reported insider equity activity by President and Chief Business Officer John Fesko. On August 6, 2026, he acquired 20,000 shares$0.006,517 shares$321.53Rule 10b5-1(c)

Natera, Inc. director and co-founder Jonathan Sheena reported selling 6,000 shares of Common Stock on August 10, 2026 in an open-market or private transaction at a weighted average price of $325.3237 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Sheena on December 12, 2025.

Following this sale, Sheena directly held 230,464 shares of Natera common stock. Additional indirect holdings of 18,032 shares are reported for each of Caraluna 1 Trust and Caraluna 2 Trust, which are held for the benefit of the trusts’ beneficiaries; Sheena disclaims beneficial ownership of those trust-held securities.

Natera, Inc. executive chairman and director Matthew Rabinowitz reported selling 2,000 shares of Common Stock on August 7, 2026 at $320.90 per share, in an open-market or private transaction under a Rule 10b5-1 plan adopted December 5, 2025. After these transactions, he held 2,275,394 shares directly and 2,000 shares indirectly through his spouse.

Natera, Inc. director and co-founder Jonathan Sheena reported open‑market sales of a total of 9,150 shares of common stock on August 7, 2026, at prices between $308.4000 and $320.9000 per share. These sales were effected under a Rule 10b5‑1 trading plan adopted on December 12, 2025. The filing also lists 18,032 shares held in each of Caraluna 1 Trust and Caraluna 2 Trust for the benefit of trust beneficiaries, and the reporting person disclaims beneficial ownership of those securities.

Natera, Inc. executive Michael Burkes Brophy, the Chief Financial Officer, reported two sales of common stock totaling 795 shares. On August 3, 2026, he sold 317 shares at $267.9893 per share to satisfy tax withholding and remittance obligations arising from the vesting of RSUs, under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. On August 4, 2026, he sold 478 shares at $274.22 per share, with those sales effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2025 and modified on September 10, 2025. The filing also checks the Rule 10b5-1 affirmative-defense box, indicating these transactions were executed under Rule 10b5-1 trading arrangements.

Natera, Inc. director, CEO and President Steven Leonard Chapman reported selling 3,076 shares of Common Stock on August 3, 2026. One sale of 1,182 shares at $267.9893 was to satisfy tax withholding and remittance obligations on vesting RSUs under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions. Additional tranches, ranging from 70 to 612 shares, were sold under a pre-arranged Rule 10b5-1 trading plan adopted December 11, 2023 and later amended, at per-share or weighted-average prices in ranges such as $263.29–$264.24, $266.58–$267.54 and $267.8350–$268.7700.

Natera, Inc. executive John Fesko, President and Chief Business Officer, reported a sale of 295 shares of common stock on August 3, 2026 at an average price of $267.9893 per share. The sale was effected to satisfy tax withholding and remittance obligations arising from vesting RSUs, pursuant to a written instruction under a Rule 10b5-1(c) Stock Unit Agreement granted on January 31, 2025. Following this transaction, Fesko directly holds 183,774 shares of Natera common stock.

Natera, Inc. executive Solomon Moshkevich, president of clinical diagnostics, reported selling a total of 3,410 shares of common stock on 2026-08-03 in multiple open-market transactions. Per-share prices included $267.9893 and $259.9800. 410 shares were sold to satisfy tax withholding on RSU vesting under instructions intended to meet Rule 10b5-1(c) conditions, and the remaining sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.

Natera, Inc. reporting person Daniel Rabinowitz, SEC. and Chief Legal Officer, reported the sale of 334 shares of Common Stock on August 3, 2026 at a per share price of $267.9893. The sale satisfied tax withholding on vesting RSUs under written Rule 10b5-1(c) instructions, leaving 170,073 shares directly held.

Natera, Inc. reports that Executive Chairman Matthew Rabinowitz sold 731 shares of common stock on 2026-08-03 at $267.9893 per share. The sale was effected to cover tax withholding and remittance obligations from RSU vesting under a Rule 10b5-1(c) instruction. After the transaction he holds 2,275,394 shares directly and 4,000 shares indirectly through his spouse.

Natera, Inc. director and co-founder Jonathan Sheena sold 109 shares of Common Stock on 2026-08-03 at $267.9893 per share. The sale was effected to satisfy tax withholding and remittance obligations arising from the vesting of RSUs and was carried out pursuant to a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c), contained in a Stock Unit Agreement granted on January 31, 2025. Following the sale, Sheena held 245,614 shares directly. Separate holdings of 18,032 shares each are reported for the Caraluna 1 Trust and Caraluna 2 Trust for the benefit of trust beneficiaries, with Sheena disclaiming beneficial ownership of those securities.

Natera, Inc. director and co‑founder Sheena Jonathan reported selling 288 and 191 shares of common stock on July 27 and 28, 2026 at average prices of $260.4908 and $254.0696 per share. The sales were effected to satisfy tax withholding obligations arising from vesting RSUs, under written instructions intended to meet Rule 10b5-1(c) conditions. Separate Caraluna 1 and Caraluna 2 trusts each hold 18,032 shares for beneficiaries, and the reporting person disclaims beneficial ownership of those securities.

Natera, Inc. Executive Chairman Matthew Rabinowitz sold 1,718 shares of Common Stock on July 27, 2026 at an average price of $260.4908 per share. The sale was effected to satisfy tax withholding and remittance obligations in connection with RSU vesting and was made under a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Following the transaction, he directly holds 2,276,125 shares, with an additional 4,000 shares held indirectly by his spouse.

Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold a total of 1,887 shares of common stock in two transactions on July 27–28, 2026. The sales, at prices around $260.4908 and a weighted-average $254.0704 per share, were effected to satisfy tax withholding and remittance obligations upon RSU vesting under written instructions intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Natera, Inc. officer Solomon Moshkevich, President, Clinical Diagnostics, reported selling a total of 2,214 shares of common stock on July 27-28, 2026. The sales were to satisfy tax withholding obligations from vesting RSUs and were executed under written instructions intended to meet Rule 10b5-1(c) conditions.

Natera, Inc. president and chief business officer John Fesko reported open-market sales totaling 1,713 shares of common stock on July 27–28, 2026. These sales were executed to satisfy tax withholding and remittance obligations arising from vesting RSUs and were made under written Rule 10b5-1 trading instructions.

The transactions included 782 shares at $260.4908 per share and 931 shares at a weighted average price of $254.0705, with individual trades on July 28 priced between $254.0696 and $254.3500 per share.

Steven Leonard Chapman, CEO and President of Natera, Inc., reported sales of 5,770 shares of common stock on July 27–28, 2026. He sold 2,190 shares at $260.4908 per share and 3,580 shares at a weighted average price of $254.0704. Footnotes state the shares were sold to satisfy tax withholding and remittance obligations upon vesting of RSUs, under written instructions intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Natera, Inc.’s Chief Financial Officer, Brophy Michael Burkes, reported open-market sales of 5,064 shares of common stock on July 27–29, 2026. Individual trades ranged from 170 to 1,863 shares, with reported prices such as $260.4908 and $249.3800 per share. Certain sales were executed to satisfy tax withholding from vesting RSUs, and all transactions were carried out under a Rule 10b5-1 trading plan adopted June 9, 2025 and modified September 10, 2025.

Natera, Inc. insider Sheena Jonathan, a director and co‑founder, reported pre‑planned sales of common stock held by family trusts. Caraluna 1 and Caraluna 2 Trusts sold a total of 1,500 shares on July 15, 2026 at weighted‑average prices between $272.56 and $276.38 per share under a Rule 10b5-1 trading plan adopted June 7, 2024. The shares are held for trust beneficiaries, and Jonathan disclaims beneficial ownership. A separate holdings entry reports 246,202 common shares held directly.

Natera, Inc. director Rowan E Chapman sold 135 shares of Common Stock on July 15, 2026 at an average price of $274.82 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on December 12, 2025, leaving Chapman with 4,663 shares held directly.

Natera, Inc. director and co‑founder Sheena Jonathan reported open‑market sales of 3,150 shares of common stock on July 13, 2026, at weighted‑average prices from $262.7160 to $268.3870 per share under a Rule 10b5‑1 trading plan adopted December 12, 2025. After these transactions, she reports 246,202 shares held directly, and 18,782 shares in each of the Caraluna 1 Trust and Caraluna 2 Trust held for trust beneficiaries, for which she disclaims beneficial ownership.

Natera, Inc. executive chairman Matthew Rabinowitz reported insider transactions involving the company’s common stock. On July 6, 2026, his spouse completed an open‑market sale of 1,000 shares at $280 per share under a pre‑arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following this sale, indirect holdings by his spouse totaled 4,000 shares, while Rabinowitz’s direct ownership stood at 2,277,843 shares, indicating the sale was small relative to his overall position.

Natera, Inc. insider Daniel Rabinowitz, the Secretary and Chief Legal Officer, sold 16,800 shares of Common Stock in a series of open‑market transactions. The sales occurred on July 1, 2026 and were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 5, 2025.

The reported sales were broken into multiple trades at weighted‑average prices, with underlying individual trade prices ranging from about $266.33 to $278.78 per share, according to the footnotes. The filing does not change any company fundamentals; it simply discloses these planned insider stock sales.

Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported selling 3,000 shares of Natera common stock in open-market transactions on July 1, 2026. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024, indicating the trades were scheduled in advance. Reported weighted average prices were about $274.06, $272.99, and $267.19 per share, with actual trade prices ranging between $267.05 and $273.00. Moshkevich continues to hold a direct equity stake in Natera after these sales.

Rubin Eric H reported acquisition or exercise transactions in this Form 4 filing.

Natera, Inc. director Eric H. Rubin received a grant of 75 Restricted Stock Units (RSUs) of Common Stock as part of his board compensation. The award was issued in lieu of quarterly retainer fees of $16,875 and was fully vested at the time of issuance. Each RSU represents a right to receive one share of Natera common stock, and following this grant Rubin holds 2,204 shares directly.

Natera, Inc. director Herm Rosenman reported two equity compensation awards in the form of restricted stock units (RSUs). The filing shows awards covering 106 shares and 1,571 shares of Common Stock, both recorded as acquisitions with no cash paid per share.

One RSU grant will vest in full on June 11, 2027 and will become fully vested earlier if Natera undergoes a change in control. The other RSU award was issued in lieu of quarterly board retainer fees of $23,750 and was fully vested upon issuance, effectively substituting stock-based compensation for cash fees.

Marcus Gail Boxer reported acquisition or exercise transactions in this Form 4 filing.

Natera, Inc. director Marcus Gail Boxer reported two stock-based compensation awards in the form of restricted stock units (RSUs). He received 98 RSUs that vest in full on June 11, 2027, and these RSUs will become fully vested if Natera undergoes a change in control before that date.

He also received 1,571 RSUs in lieu of $21,875 in quarterly cash retainer fees for serving on the board. These RSUs were fully vested when issued. Each RSU represents a right to receive one share of Natera common stock, so these are non-cash equity grants rather than open-market share purchases.

Natera, Inc. director Thomas J. Lynch Jr. reported an equity compensation grant on Common Stock. He acquired 1,905 shares in the form of Restricted Stock Units (RSUs) at no cash cost, bringing his directly held total reported in this filing to 1,905 shares.

The RSU award is valued at $425,000 and will vest in three equal annual installments beginning on June 2, 2027. Each RSU represents a contingent right to receive one share of Natera’s Common Stock as it vests over time.

Chapman Rowan E reported acquisition or exercise transactions in this Form 4 filing.

Natera, Inc. director Rowan E. Chapman reported receiving equity-based compensation in the form of restricted stock units (RSUs). One grant covers 103 RSUs that will vest in full on June 11, 2027, and will vest earlier if Natera undergoes a change in control. A second grant of 1,571 RSUs was issued in lieu of $23,125 in quarterly board retainer fees and was fully vested at issuance. Each RSU represents a contingent right to receive one share of Natera common stock, so these awards increase the director’s potential future share ownership without any cash outlay.

BOTHA ROELOF reported acquisition or exercise transactions in this Form 4 filing.

Natera, Inc. director Roelof Botha reported new equity awards in the form of restricted stock units (RSUs). He received 1,571 RSUs that vest in full on June 11, 2027, with full vesting if Natera undergoes a change in control, and 120 RSUs issued in lieu of quarterly board retainer fees of $26,875, which were fully vested at issuance. Each RSU represents one share of Natera common stock. Following these grants, Botha holds 4,585 shares of common stock directly and 1,076,198 shares indirectly through estate planning vehicles, indicating these awards are small relative to his overall position.

Bertagnolli Monica reported acquisition or exercise transactions in this Form 4 filing.

Natera, Inc. director Monica Bertagnolli reported two stock-based compensation grants. She received 75 restricted stock units (RSUs) that will vest in full on June 11, 2027, or sooner if Natera undergoes a change in control. She also received 1,571 RSUs issued in lieu of quarterly board retainer fees of $16,875, which were fully vested at issuance. Each RSU represents the right to receive one share of Natera common stock, increasing her equity-based compensation without an open-market stock purchase.

Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.

Natera, Inc. director Roy D. Baynes reported receiving equity compensation in the form of restricted stock units (RSUs). One grant covers 75 RSUs that will vest in full on June 11, 2027, with full vesting also triggered if the company undergoes a change in control.

A separate award of 1,571 RSUs was issued in lieu of cash quarterly retainer fees of $16,875 for board service and was fully vested at issuance. Each RSU represents a contingent right to receive one share of Natera’s common stock, aligning a portion of director compensation with future share value.

Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold a total of 33,600 shares of Common Stock in open-market transactions on June 24, 2026. The sales were executed at weighted average prices between about $250 and $253 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following these transactions, Rabinowitz directly holds 189,094 shares of Natera Common Stock.

Natera, Inc. director Herm Rosenman reported an open-market sale of 16,530 shares of Natera common stock on June 24, 2026 at $250.00 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Following this sale, Rosenman directly holds 4,250 shares of Natera common stock.

Natera, Inc. director and co-founder Sheena Jonathan reported pre-planned sales of company stock by family trusts. On June 17, 2026, Caraluna 1 and Caraluna 2 Trusts together sold 1,500 shares of Natera common stock in a series of open-market transactions under a Rule 10b5-1 trading plan adopted on June 7, 2024. The sales were executed at weighted average prices around the low- to mid-$220 per share range, based on multiple trades within narrow price bands. After these transactions, Jonathan continues to report 249,352 shares held directly, while Caraluna 1 Trust holds 19,276 shares and Caraluna 2 Trust holds 19,265 shares. The filing notes the trusts hold shares for their beneficiaries and that Jonathan disclaims beneficial ownership of the trust-held securities.

Natera, Inc. director Rowan E. Chapman sold shares in an open-market transaction. On June 16, 2026, Chapman sold 2,964 shares of Natera common stock at an average price of $216.78 per share.

Following the sale, Chapman directly held 3,124 Natera shares. The filing notes that this transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating it was scheduled in advance rather than timed discretionarily.

Natera, Inc. director and co-founder Sheena Jonathan reported open-market sales of the company’s common stock. On June 15, 2026, she sold a total of 3,150 shares in several transactions at prices around $210–$214 per share, as reflected by weighted average prices in the filing.

The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance. Following these transactions, Jonathan holds 249,352 shares of Natera common stock directly. Additional shares are held indirectly through the Caraluna 1 and Caraluna 2 Trusts for the benefit of trust beneficiaries, and she disclaims beneficial ownership of those securities.

Natera, Inc. executive chairman Matthew Rabinowitz reported open-market sales of a total of 100,000 shares of common stock. The transactions took place on June 12 and June 15, 2026 at weighted average prices within ranges from $208.88 to $219.98 per share, according to accompanying footnotes.

The filing states that these sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. Following the transactions, Rabinowitz directly holds 2,277,843 common shares, with an additional 5,000 shares held indirectly by his spouse, indicating he retains a substantial equity position in the company.

Natera, Inc. director Marcus Gail Boxer reported an exercise-and-sell transaction in company stock. On June 5, 2026, he exercised stock options for 11,000 shares of Common Stock at an exercise price of $22.83 per share and sold 11,000 shares in multiple open-market trades.

The sales were executed in several tranches at weighted average prices around $216–$219 per share, with detailed price ranges disclosed in the notes. Following these transactions, Boxer directly owns 6,183 shares of Natera Common Stock, and the option position related to these 11,000 shares is fully exercised.

Natera, Inc. CEO and President Steven Leonard Chapman reported open-market sales of 41,124 shares of common stock on June 4, 2026. The 14 separate transactions were executed at weighted-average prices, with footnotes showing sale prices ranging from about $211.89 to $227.21 per share under a pre-arranged Rule 10b5-1 trading plan adopted and later amended by the reporting person. After these sales, Chapman continues to hold 108,743 shares of Natera common stock directly.

Natera, Inc. president of clinical diagnostics Solomon Moshkevich sold 3,000 shares of common stock in open-market transactions. The trades on June 1, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan and at various prices. After these sales, he directly holds 137,643 shares.

Rubin Eric H reported acquisition or exercise transactions in this Form 4 filing.

Natera, Inc. director Eric H. Rubin received a grant of 2,124 shares of Common Stock in the form of Restricted Stock Units as compensation. The award is valued at $425,000 and increases his direct holdings to 2,129 shares.

The RSUs will vest in three equal annual installments beginning on March 26, 2027. Each RSU represents a contingent right to receive one share of Natera’s Common Stock, so Rubin will receive the underlying shares over time as the units vest.

Natera, Inc. director Roelof Botha reported a series of open-market sales totaling 78,000 shares of Natera common stock on June 1, 2026, executed through estate planning vehicles. The reported weighted average sale prices ranged from about $218 to $224 per share across multiple trades. Following these transactions, estate planning vehicles associated with Botha held 1,076,198 shares indirectly, while he also reported 2,894 shares held directly.

Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported an open-market sale of 1,652 shares of common stock at $202.8398 per share. According to the footnote, the sale was made to satisfy tax withholding obligations tied to RSU vesting under a written instruction intended to meet Rule 10b5-1(c) conditions. Following the transaction, he directly holds 140,643 shares.

Natera, Inc. reported that its President and Chief Business Officer, John Fesko, sold 1,438 shares of common stock in an open-market transaction at an average price of $202.8398 per share. The sale was made to cover tax withholding obligations related to the vesting of restricted stock units and followed written instructions intended to satisfy Rule 10b5-1(c) conditions. After this transaction, Fesko directly holds 185,782 shares of Natera common stock.

Natera, Inc. co-founder and director Sheena Jonathan reported 13 sales totaling 4,650 shares of Natera common stock on May 8 and May 13, 2026, at weighted-average prices between $199.00 and $210.3450 per share, effected under Rule 10b5-1 trading plans. After these trades, she holds 252,502 shares directly, with 19,532 shares held by Caraluna 1 Trust and 19,532 shares by Caraluna 2 Trust; the trust shares are held for beneficiaries, and Jonathan disclaims beneficial ownership of those securities.

Natera, Inc. Executive Chairman Matthew Rabinowitz reported compensation-related stock activity. On May 5, 2026, he received 2,389 fully vested Restricted Stock Units (RSUs), each representing one share of common stock. Around the same time, he sold 7,708 shares of common stock in multiple open-market transactions at prices between $205.22 and $241.39.

According to the footnotes, these sales were executed to satisfy tax withholding and remittance obligations arising from RSU vesting and were carried out under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c). After these transactions, he directly owned 2,378,791 shares of Natera common stock, with an additional 5,000 shares held indirectly by his spouse.

Natera, Inc. chief financial officer Michael Burkes Brophy reported selling a total of 795 shares of Common Stock in open-market transactions, including 313 shares at $206.16 on May 1, 2026 and 482 shares at $210.49 on May 4, 2026. According to the footnotes, these sales were carried out to satisfy tax withholding obligations related to vesting RSUs and were executed under written instructions and a Rule 10b5-1 trading plan. After these transactions, he directly holds 57,496 shares.